An analysis of the utilisation and expenditure of medicines dispensed for the prophylaxis and treatment of osteoporosis
Publisher:
National Centre for PharmacoeconomicsDate published:
3 February, 2007Region:
Republic of Ireland Publication type:
researchFeatured item on home page:
no
Osteoporosis is a skeletal disease characterised by low bone mass and microarchitectural deterioration with a resulting increase in bone fragility and therefore increased risk of fracture[1]. It occurs predominantly in postmenopausal women and in patients who are taking long-term oral corticosteroids (glucocorticosteroids)[2]. Other factors which increase the risk of developing osteoporosis are low body weight, cigarette smoking, excess alcohol intake, lack of physical activity, family history of osteoporosis and early menopause.
Similar entries
- Aspirin may be useful for osteoporosis
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis
- Milk cuts later osteoporosis risk
- Causes and consequences of rib fractures in older men
- Osteoporosis in the elderly
- World Osteoporosis Day tomorrow
- Them bones need calcium
- NICE issues final guidance on preventing fractures due to osteoporosis
- The Silver Book:Osteoporosis
- Fractures in the elderly often difficult to heal



